Truist Securities on AdaptHealth (AHCO) Amid CFO Change

Truist Securities analyst David MacDonald reiterated a Buy rating and $9.00 price target on AdaptHealth (NASDAQ: AHCO).

The analyst commented: "CFO Change Announced. After the close, AHCO filed an 8-K announcing the appointment of Harriss Currie as the company's CFO effective 9/9 with former CFO Jason Clemens assisting in the transition through 10/1. The announcement comes on the heels of disappointing recent results and a challenging 2Q marked by a sizable core guidance cut (excluding Diabetes divestiture impact) tied largely to underperformance within the large Kaiser capitated contract and a manufacturer price increase. Mr. Currie brings meaningful public company experience and joins AHCO following CFO roles at Health Track Rx (Private) from 2025 - 2026, Impulse Dynamics (Private) from 2022 - 2023 and Luminex Corp (LMNX which was bought by DIA, NR in 2021) for 15+ years, while he also served as the President of the Regenerative Medicine division of 3D Systems (DDD, NR) from 2023 - 2025. Finally, while we are encouraged by strong organic revenue growth trends and view the recent agreement to divest the Diabetes business favorably, we look for tangible signs of recovery over the coming quarters and continue to view the name as a near-term show me story where execution is key."

For an analyst ratings summary and ratings history on AdaptHealth click here. For more ratings news on AdaptHealth click here.

Shares of AdaptHealth closed at $6.19 yesterday.

You May Also Be Interested In

• Diamondrock Hospitality (DRH) PT Raised to $13.50 at Stifel
• BMO Capital Reiterates Outperform Rating on Scholar Rock (SRRK)
• Cooper Companies (COO) PT Lowered to $75 at Mizuho, 'remains undervalued'